Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 10:20 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 879 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Placebo Surgery Control Clear all
Not listed Phase 2Phase 3 Interventional

A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

NCT05660447
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 29, 2026, 10:20 PM EDT
Completed Phase 2 Interventional

Analgesic Efficacy and Safety of ADL5859 in Subjects With Acute Dental Pain After Third Molar Extraction

NCT00993863
View directory record Official record
Conditions
Acute Pain
Interventions
Placebo, ADL5859 30 mg, ADL5859 100 mg, ADL5859 200 mg, ibuprofen 400 mg
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2015 · Synced Oct 29, 2026, 10:20 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

NCT04281108
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Drug · Procedure
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Anniston, Alabama • Dothan, Alabama • Mobile, Alabama + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 29, 2026, 10:20 PM EDT
Completed Phase 3 Interventional

A Study to Evaluate Safety and Efficacy Following Dosing of Oxycodone/Naltrexone for Treatment of Adults With Pain Following Bunionectomy Surgery

NCT02401750
View directory record Official record
Conditions
Pain
Interventions
Oxycodone Naltrexone (a), Oxycodone Naltrexone (b), Placebo
Drug
Lead sponsor
Elite Laboratories, Inc
Industry
Eligibility
18 Years to 75 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
5
States / cities
Phoenix, Arizona • Pasadena, Maryland • Austin, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2016 · Synced Oct 29, 2026, 10:20 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Trial of Levator Muscle Blocks Following Posterior Colporrhaphy Surgery to Reduce Post-operative Pain.

NCT03067168
View directory record Official record
Conditions
Post Operative Pain
Interventions
Bupivacaine, normal saline 0.9%
Drug
Lead sponsor
The Christ Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
3
States / cities
Kansas City, Kansas • Cincinnati, Ohio • Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Oct 29, 2026, 10:20 PM EDT
Recruiting Phase 1Phase 2 Interventional

CBD for Pain Following Orthopedic Shoulder Surgery

NCT06381791
View directory record Official record
Conditions
Shoulder Osteoarthritis, Rotator Cuff Injuries
Interventions
Epidiolex, Placebo oral solution
Drug
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 29, 2026, 10:20 PM EDT
Terminated Phase 4 Interventional

Clinical Trial of Solifenacin Versus Placebo Plus Pessary for Women With Vaginal Prolapse

NCT01092624
View directory record Official record
Conditions
Pelvic Organ Prolapse
Interventions
Solifenacin, Placebo, Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex
Drug · Device
Lead sponsor
Hartford Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 4, 2011 · Synced Oct 29, 2026, 10:20 PM EDT
Completed Phase 3 Interventional Results available

Evaluating Outcomes in Cardiac Surgery Patients Who Receive Sugammadex vs. Placebo

NCT05801679
View directory record Official record
Conditions
Surgery
Interventions
Sugammadex, Placebo
Drug · Other
Lead sponsor
Endeavor Health
Other
Eligibility
21 Years to 90 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Oct 29, 2026, 10:20 PM EDT
Not yet recruiting Phase 4 Interventional

Aprepitant to Improve Same Day Discharge for TKA

NCT07639723
View directory record Official record
Conditions
PONV
Interventions
Aprepitant Injection, Ondansetron (Zofran), Dexamethasone, Placebo
Drug · Other
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 90 Years
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Skokie, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 29, 2026, 10:20 PM EDT
Completed Phase 3 Interventional Results available

Patients With Metastatic Colorectal Cancer Treated With Regorafenib or Placebo After Failure of Standard Therapy

NCT01103323
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Regorafenib (Stivarga, BAY73-4506), Placebo, Best Supportive Care (BSC)
Drug · Other
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
26
States / cities
Beverly Hills, California • Los Angeles, California • Mission Hills, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2015 · Synced Oct 29, 2026, 10:20 PM EDT
Completed Phase 3 Interventional Results available

Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.

NCT00781859
View directory record Official record
Conditions
Vitreomacular Adhesion
Interventions
125 µg Ocriplasmin, Placebo
Drug
Lead sponsor
ThromboGenics
Industry
Eligibility
18 Years and older
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
41
States / cities
Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2014 · Synced Oct 29, 2026, 10:20 PM EDT
Completed Phase 1 Interventional

PDE5 Inhibition Via Tadalafil to Enhance Anti-Tumor Mucin 1 (MUC1) Vaccine Efficacy in Patients With HNSCC

NCT02544880
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma, Head and Neck Cancer
Interventions
Tadalafil, Anti-MUC1 Vaccine, Anti-Influenza Vaccine, Tadalafil Placebo, Anti-MUC1 Vaccine Placebo, Standard of Care Treatment, Anti-Influenza Vaccine Placebo
Drug · Biological · Other
Lead sponsor
Donald T. Weed, MD, FACS
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 15, 2021 · Synced Oct 29, 2026, 10:20 PM EDT
Completed Phase 3 Interventional Results available

Effect of Nitric Oxide in Cardiac Surgery Patients With Endothelial Dysfunction.

NCT02836899
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Nitric Oxide, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 29, 2026, 10:20 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Trial of Testosterone Undecanoate for Optimizing Performance During Military Operations

NCT04120363
View directory record Official record
Conditions
Caloric Restriction, Exercise, Sleep
Interventions
Testosterone Undecanoate, Sesame Oil
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 35 Years · Male only
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 7, 2022 · Synced Oct 29, 2026, 10:20 PM EDT
Terminated Phase 3 Interventional

Vapreotide in Treating Patients Undergoing Elective Pancreatic Resection

NCT00014651
View directory record Official record
Conditions
Pancreatic Cancer, Perioperative/Postoperative Complications
Interventions
vapreotide, conventional surgery
Drug · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 90 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
18
States / cities
Birmingham, Alabama • Tampa, Florida • Chicago, Illinois + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2010 · Synced Oct 29, 2026, 10:20 PM EDT
Completed Phase 4 Interventional Results available

Efficacy of Propofol or Midazolam Compare to Placebo for Preoperative Medication

NCT01976845
View directory record Official record
Conditions
Elective Orthopedic Surgery
Interventions
Midazolam, Propofol, Saline
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 29, 2026, 10:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Nitrous Oxide for Pain Management During In-office Transcervical Sterilization

NCT02312739
View directory record Official record
Conditions
Contraception, Inhalation of Nitrous Oxide
Interventions
In-office Transcervical Sterilization (Essure®), Standard Oral pain medications, Intramuscular Ketorolac, Placebo pills, Oxygen, Nitrous Oxide
Procedure · Drug · Other
Lead sponsor
University of New Mexico
Other
Eligibility
21 Years and older · Female only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 6, 2016 · Synced Oct 29, 2026, 10:20 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain

NCT00226395
View directory record Official record
Conditions
Acute Pain
Interventions
Oxymorphone immediate release
Drug
Lead sponsor
Endo USA Inc., a Keenova Therapeutics Company
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
21
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 2, 2024 · Synced Oct 29, 2026, 10:20 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Multicenter, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Clinical Efficacy, Safety, and Tolerability of ARX-F01 Sublingual Sufentanil in Patients Undergoing Major Abdominal Surgery

NCT00718081
View directory record Official record
Conditions
Major Upper or Lower Abdominal Surgery
Interventions
Oral sufentanil, Placebo
Drug
Lead sponsor
Talphera, Inc
Industry
Eligibility
18 Years to 80 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 22, 2015 · Synced Oct 29, 2026, 10:20 PM EDT
Not listed Phase 1Phase 2 Interventional

Prospective Evaluation of PRP and BMC Treatment to Accelerate Healing After ACL Reconstruction

NCT04205656
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
Leukocyte-Poor Platelet Rich Plasma (LP-PRP), Bone Marrow Concentrate (BMC), Control group (Placebo)
Biological · Other
Lead sponsor
Steadman Philippon Research Institute
Other
Eligibility
16 Years to 50 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Vail, Colorado
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 29, 2026, 10:20 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Can Testosterone Accelerate Injury Recovery After Arthroscopic Rotator Cuff Repair

NCT04345666
View directory record Official record
Conditions
Rotator Cuff Tears
Interventions
Testosterone cypionate, Placebos
Drug
Lead sponsor
Orthopedic Institute, Sioux Falls, SD
Other
Eligibility
45 Years to 75 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Oct 29, 2026, 10:20 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Randomized Controlled Trial of Three Antibiotic Regimens for First Trimester Abortions

NCT02756403
View directory record Official record
Conditions
First Trimester Abortion
Interventions
Azithromycin, Doxycycline, Metronidazole, Placebo
Drug
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Silver Spring, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 11, 2022 · Synced Oct 29, 2026, 10:20 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate LB1148 for Return of Gastrointestinal Function and Adhesions in Subjects Undergoing Bowel Resection

NCT02836470
View directory record Official record
Conditions
Ileus, Post-Operative Adhesions
Interventions
LB1148, Placebo
Drug
Lead sponsor
Palisade Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
28
States / cities
Mobile, Alabama • Yuma, Arizona • Irvine, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 29, 2026, 10:20 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of Gabapentin to Decrease Postoperative Delirium and Pain

NCT00221338
View directory record Official record
Conditions
Postoperative Delirium, Postoperative Pain, Opioid Use, Hospital Length of Stay
Interventions
Gabapentin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
65 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 29, 2026, 10:20 PM EDT